Biblio
Toll-like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies. Transpl Immunol. 2016.
T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation. Nagoya J Med Sci. 2023;85(4):779-796.
Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia. Cytotherapy. 2024.
Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2021.
Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine. Cancer Sci. 2021.
Favorable Outcome with Conditioning Regimen of Flu/Bu4/Mel in Acute Myeloid Leukemia Patients in Remission Undergoing Cord Blood Transplantation. Transplant Cell Ther. 2022.
Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics. Ann Hematol. 2023.
Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation. Int J Hematol. 2023.
Conditioning intensity for allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with poor-prognosis cytogenetics in first complete remission. Biol Blood Marrow Transplant. 2019.